Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Operating Leases (2019 - 2026)

Denali Therapeutics has reported Operating Leases over the past 7 years, most recently at $27.2 million for Q4 2025.

  • Quarterly Operating Leases fell 25.8% to $27.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.2 million through Dec 2025, down 25.8% year-over-year, with the annual reading at $27.2 million for FY2025, 25.8% down from the prior year.
  • Operating Leases was $27.2 million for Q4 2025 at Denali Therapeutics, down from $38.8 million in the prior quarter.
  • Over five years, Operating Leases peaked at $62.9 million in Q1 2021 and troughed at $27.2 million in Q4 2025.
  • The 5-year median for Operating Leases is $50.9 million (2022), against an average of $49.1 million.
  • Year-over-year, Operating Leases rose 0.0% in 2024 and then tumbled 34.14% in 2025.
  • A 5-year view of Operating Leases shows it stood at $58.6 million in 2021, then decreased by 9.43% to $53.0 million in 2022, then fell by 15.18% to $45.0 million in 2023, then dropped by 18.47% to $36.7 million in 2024, then fell by 25.8% to $27.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Operating Leases are $27.2 million (Q4 2025), $38.8 million (Q3 2025), and $32.1 million (Q2 2025).